seen from United States
seen from China
seen from China
seen from Canada
seen from Russia
seen from United States
seen from Malaysia

seen from United States
seen from Netherlands
seen from France

seen from United States
seen from United States

seen from Singapore

seen from China
seen from United States
seen from Netherlands
seen from United States
seen from Netherlands
seen from United Kingdom
seen from United States

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
“ so this is fun... ” | @hshqstarters
table 1 https://ift.tt/2LHSDwn
Tension between tables?
A little birdy told me KQ got into some trouble with the staff which definitely pleased Table 1. However, KQ’s table aka Table 4 weren’t all in agreement with what happened with KQ. Some overheard KQ’s buddies arguing over whether or not to “stand up” for KQ, even though she’s in the wrong majority of the time. All I can say is DT’s show of loyalty impressed me considering how fast she abandoned her old group
~Catty Cougar
I'll take the vaginal intercourse please .... With a side of eggs
Table 1 and hurry please .

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Dear Dr. G,
We noticed that you flipped the script on the SFC (Salmeterol/Fluticasone Propionate) and FP (Fluticasone Propionate) randomized populations in Tables 1 and 2, what's up with that?
Sincerely,
Research FAIL
p.s. this study was funded by GlaxoSmithKline
Glaucoma FAIL #1
Dr. B,
Here is a list of all the errors that I found in Table 1:
1. Under the BIM column (sex), the number of participants (male/female) do not add up to the amount of participants in the BIM treatment group (132+157=289 NOT 265)
2. Under the TIM column (sex), the number of participants (male/female) do not add up to the amount of participants in the TIM treatment group (140+146 = 286 NOT 263)
3. When the number of participants were added up for the overall number of females in all treatment groups, the sum does not add up (Female: 286+132+140= 558 NOT 588)
4. When the number of participants were added up for the overall number of males in all treatment groups, the sum does not add up (Male: 247+157+146 =550 NOT 503)
5. Under Race, when the number of all participants are summed up (excluding non-black), the sum does not equal the overall participant number of 1061 (774 + 14 + 92 + 176 = 1056 NOT 1061)
6. When the number of participants were added up for the overall number of light iris colors in all treatment groups, the sum does not add up (278 + 117 + 128 = 523 NOT 452)
7. When the number of participants were added up for the overall number of dark iris colors in all treatment groups, the sum does not add up (255 + 148 + 135 = 538 NOT 261)
8. when the percentages of the participants' eye colors)were added up, it does not equal 100%, not even close (42.6%+24.6%=67.2% NOT 100%)
9. Another percentage error is found in the TIM column for Glaucoma diagnosis, does not equal/approach 100% (54.8%+54.8%+2.3%=111.9%)
10. Under the TIM column (Glaucoma diagnosis), the number of participants do not add up to the amount of participants in the TIM treatment group (144 + 144 + 6 = 294 NOT 263)
11. When the number of participants were added up for the overall number of glaucoma diagnoses in all treatment groups, the sum does not add up for Ocular hypertension OU (228 + 113 + 144 = 485 NOT 585)
12. When the number of participants were added up for the overall number of glaucoma diagnoses in all treatment groups, the sum does not add up for Glaucoma OU (292 + 149 + 144 = 585 NOT 454)
Sincerely,
Research FAIL
p.s. this study was funded by Allergan